Skip to main content

An update on the epidemiology of aspirin-exacerbated respiratory disease

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.


Aspirin-exacerbated respiratory disease (AERD) is a disorder of nasal polyposis, asthma, and hypersensitivity respiratory reactions when on systemic cyclooxygenase 1 blockade.


AERD warrants specific evaluation as an endotype of asthma and chronic sinus disease due to unique therapeutic opportunities. Currently, aspirin therapy is uniquely beneficial as an anti-inflammatory therapy in AERD, with multiple additional therapies currently in early to late clinical studies, which might also show exceptional benefit in AERD.


Yet, given the lack of a simple diagnostic test, opportunities to identify patients with AERD are still frequently neglected.


Identifying the prevalence and population characteristics necessary to determine appropriate candidates in whom to perform diagnostic aspirin challenge remains critically important and was the purpose of this article.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: AERD; Aspirin-exacerbated respiratory disease; NSAID exacerbated respiratory disease; Samter syndrome; aspirin intolerance; epidemiology; prevalence

Document Type: Research Article

Affiliations: Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, California, USA

Publication date: 01 September 2017

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more